Effects of propranolol and metoprolol on glucose, cyclic AMP and insulin responses during pharmacologic hyperglucagonemia in hemodialysis patients.
Propranolol-induced hypoglycemia in hemodialysis patients has been increasingly recognized. We studied the effects of a nonselective beta-blocker (propranolol) and a beta 1-selective-blocker (metoprolol) on glucose metabolism during pharmacologic hyperglucagonemia in these patients. cAMP and insulin responses to glucagon were noted to be significantly higher in all patients after dialysis. This may possibly be due to the removal of a dialyzable factor suppressing these responses. However, despite a similar cAMP response, patients on propranolol had significantly lower glucose response than those not receiving beta-blocker before and after dialysis. While patients on metoprolol also had impaired glucose response before dialysis, this significantly improved after dialysis possibly due to the removal of active metabolite(s). Results suggest that metoprolol has less interference on glucose response to glucagon than propranolol in hemodialysis.
Pun
K K
KK
Yeung
C K
CK
Yeung
R T
RT
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D005260:Female; D005934:Glucagon / Q000097:blood; D005943:Gluconeogenesis / Q000187:drug effects; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007328:Insulin / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D008790:Metoprolol / Q000494:pharmacology*; D011433:Propranolol / Q000009:adverse effects / Q000494:pharmacology*; D006435:Renal Dialysis
D001786:Blood Glucose; D007328:Insulin; D008112:Liver Glycogen; D005934:Glucagon; D011433:Propranolol; D000242:Cyclic AMP; D008790:Metoprolol